Prognostic values of EDNRB in triple‑negative breast cancer

Liu,Shaoqing; Zhang,Jingyang; Zhu,Jiujun; Jiao,Dechuang; Liu,Zhenzhen

doi:10.3892/ol.2020.12012

Prognostic values of EDNRB in triple‑negative breast cancer

Authors:
- Shaoqing Liu
- Jingyang Zhang
- Jiujun Zhu
- Dechuang Jiao
- Zhenzhen Liu
View Affiliations

Affiliations: Department of Breast Surgery, Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China
Published online on: August 24, 2020 https://doi.org/10.3892/ol.2020.12012
Article Number: 149
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple‑negative breast cancer (TNBC) has a high degree of malignancy. The endothelin B receptor (EDNRB) serves an important role in the occurrence and development of cancer. The present study aimed to investigate the prognostic value of EDNRB in TNBC. A total of 99 cases of TNBC were collected from the Henan Cancer Hospital database and 159 cases of TNBC were collected from The Cancer Genome Atlas database. A χ² test was used to analyze the association between EDNRB and clinicopathological data. Kaplan‑Meier analysis and multivariate Cox regression analysis were used to analyze the association between EDNRB and prognosis, and to establish two models. The discrimination degree of the models was evaluated using time‑dependent receiver operating characteristic curves and concordance index (C‑index), whereas the accuracy and net benefit of the models were evaluated using integrated discriminant improvement (IDI) and decision curves. EDNRB expression was low in TNBC samples (P<0.01). Age (P=0.01), tumor size (P=0.04) and N stage (P=0.01) were associated with EDNRB expression. EDNRB expression was positively associated with stromal score (P<0.01), but not immune score. High expression levels of EDNRB indicated favorable disease‑free survival time (hazard ratio, 0.38; 95% CI, 0.15‑0.98; P=0.04). The integrated area under the curve and C‑index of the new model were increased compared with the old model following the addition of EDNRB expression as a parameter. The IDI values for prediction of the 3‑ and 5‑year survival rates were 0.04 (P=0.02) and 0.05 (P=0.01), respectively. The results of decision curve analysis showed that the new model had higher clinical net benefit than the old model in the range of 3‑year survival rate <0.52. In conclusion, EDNRB was associated with a favorable prognosis in patients with TNBC, and may be used as a novel prognostic biomarker.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Wang C, Kar S, Lai X, Cai W, Arfuso F, Sethi G, Lobie PE, Goh BC, Lim LHK, Hartman M, et al: Triple negative breast cancer in Asia: An insider's view. Cancer Treat Rev. 62:29–38. 2018. View Article : Google Scholar : PubMed/NCBI
3	Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
4	Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K and Masaki T: The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA. 86:2863–2867. 1989. View Article : Google Scholar : PubMed/NCBI
5	Bagnato A and Natali PG: Endothelin receptors as novel targets in tumor therapy. J Transl Med. 2:162004. View Article : Google Scholar : PubMed/NCBI
6	Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ and Maguire JJ: Endothelin. Pharmacol Rev. 68:357–418. 2016. View Article : Google Scholar : PubMed/NCBI
7	Namiki A, Hirata Y, Fukazawa M, Ishikawa M, Moroi M, Aikawa J, Yabuki S and Machii K: Endothelin-1- and endothelin-3-induced vasorelaxation via endothelium-derived nitric oxide. Jpn J Pharmacol. 58 (Suppl 2):326P1992.PubMed/NCBI
8	Vacca F, Bagnato A, Catt KJ and Tecce R: Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res. 60:5310–5317. 2000.PubMed/NCBI
9	Green DS, Rupasinghe C, Warburton R, Wilson JL, Sallum CO, Taylor L, Yatawara A, Mierke D, Polgar P and Hill N: A cell permeable peptide targeting the intracellular loop 2 of endothelin B receptor reduces pulmonary hypertension in a hypoxic rat model. PLoS One. 8:e813092013. View Article : Google Scholar : PubMed/NCBI
10	Morbidelli L, Orlando C, Maggi CA, Ledda F and Ziche M: Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. Am J Physiol. 269:H686–H695. 1995.PubMed/NCBI
11	Spinella F, Caprara V, Garrafa E, Castro V, Rosanò L, Natali PG and Bagnato A: Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells. Can J Physiol Pharmacol. 88:782–787. 2010. View Article : Google Scholar : PubMed/NCBI
12	Wülfing P, Diallo R, Kersting C, Wülfing C, Poremba C, Rody A, Greb RR, Böcker W and Kiesel L: Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin Cancer Res. 9:4125–4131. 2003.PubMed/NCBI
13	Vasaikar S, Tsipras G, Landázuri N, Costa H, Wilhelmi V, Scicluna P, Cui HL, Mohammad AA, Davoudi B, Shang M, et al: Overexpression of endothelin B receptor in glioblastoma: A prognostic marker and therapeutic target? BMC Cancer. 18:1542018. View Article : Google Scholar : PubMed/NCBI
14	Bastian PJ, Ellinger J, Heukamp LC, Kahl P, Müller SC and von Rücker A: Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol. 51:665–674. 2007. View Article : Google Scholar : PubMed/NCBI
15	Zhang L, Luo B, Dang YW, He RQ, Chen G, Peng ZG and Feng ZB: The clinical significance of endothelin receptor type B in hepatocellular carcinoma and its potential molecular mechanism. Exp Mol Pathol. 107:141–157. 2019. View Article : Google Scholar : PubMed/NCBI
16	Cancer Genome Atlas Network, . Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
17	Ren G, Tian Q, An Y, Feng B, Lu Y, Liang J, Li K, Shang Y, Nie Y, Wang X and Fan D: Coronin 3 promotes gastric cancer metastasis via the up-regulation of MMP-9 and cathepsin K. Mol Cancer. 11:672012. View Article : Google Scholar : PubMed/NCBI
18	Gu X, Han S, Cui M, Xue J, Ai L, Sun L, Zhu X, Wang Y and Liu C: Knockdown of endothelin receptor B inhibits the progression of triple-negative breast cancer. Ann N Y Acad Sci. 1448:5–18. 2019. View Article : Google Scholar : PubMed/NCBI
19	Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, et al: Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 4:26122013. View Article : Google Scholar : PubMed/NCBI
20	Belkacemi Y, Hanna NE, Besnard C, Majdoul S and Gligorov J: Local and regional breast cancer recurrences: Salvage therapy options in the new era of molecular subtypes. Front Oncol. 8:1122018. View Article : Google Scholar : PubMed/NCBI
21	Bianchini G, Balko JM, Mayer IA, Sanders ME and Gianni L: Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 13:674–690. 2016. View Article : Google Scholar : PubMed/NCBI
22	Berger Y, Bernasconi CC and Juillerat-Jeanneret L: Targeting the endothelin axis in human melanoma: Combination of endothelin receptor antagonism and alkylating agents. Exp Biol Med (Maywood). 231:1111–1119. 2006.PubMed/NCBI
23	Wülfing P, Kersting C, Tio J, Fischer RJ, Wülfing C, Poremba C, Diallo R, Böcker W and Kiesel L: Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. Clin Cancer Res. 10:2393–2400. 2004. View Article : Google Scholar : PubMed/NCBI
24	Joyce JA and Pollard JW: Microenvironmental regulation of metastasis. Nat Rev Cancer. 9:239–252. 2009. View Article : Google Scholar : PubMed/NCBI
25	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
26	Kalluri R and Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer. 6:392–401. 2006. View Article : Google Scholar : PubMed/NCBI
27	Beenken SW, Urist MM, Zhang Y, Desmond R, Krontiras H, Medina H and Bland KI: Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg. 237:732–739. 2003. View Article : Google Scholar : PubMed/NCBI
28	Kerr KF, McClelland RL, Brown ER and Lumley T: Evaluating the incremental value of new biomarkers with integrated discrimination improvement. Am J Epidemiol. 174:364–374. 2011. View Article : Google Scholar : PubMed/NCBI
29	Vickers AJ and Elkin EB: Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making. 26:565–574. 2006. View Article : Google Scholar : PubMed/NCBI